{"id":"carrellizumab-capecitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (fatigue, rash)"},{"rate":null,"effect":"Myelosuppression"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_fixedAt":"2026-03-30T13:33:03.838895","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carrellizumab enhances T-cell mediated anti-tumor immunity by preventing PD-L1-mediated immune checkpoint suppression. Capecitabine is a prodrug that converts to 5-fluorouracil in tumor tissue, inhibiting thymidylate synthase and disrupting DNA synthesis. The combination leverages immunotherapy with conventional chemotherapy for enhanced efficacy.","oneSentence":"Carrellizumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with capecitabine, a fluoropyrimidine chemotherapy agent.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:58.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric or gastroesophageal junction cancer (Phase 3 development)"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT06313463","phase":"PHASE3","title":"Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03","conditions":"Breast Neoplasms","enrollment":375}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2023","pmid":"37841278","title":"Case Report: Complete pathological remission of human chorionic gonadotrophin-producing gallbladder carcinoma with multiple liver metastases after treatment with chemotherapy plus an immune checkpoint inhibitor.","journal":"Frontiers in immunology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Carrellizumab + Capecitabine","genericName":"Carrellizumab + Capecitabine","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carrellizumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with capecitabine, a fluoropyrimidine chemotherapy agent. Used for Gastric or gastroesophageal junction cancer (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}